Corresponding Author: Carol M. Mangione, MD, MSPH, David Geffen School of Medicine, University of California, Los Angeles, 1100 Glendon Avenue, Suite 900, Los Angeles, CA 90024 (firstname.lastname@example.org).
Accepted for Publication: March 31, 2022.
The US Preventive Services Task Force (USPSTF) members: Carol M. Mangione, MD, MSPH; Michael J. Barry, MD; Wanda K. Nicholson, MD, MPH, MBA; Michael Cabana, MD, MA, MPH; Aaron B. Caughey, MD, MPH; David Chelmow, MD; Tumaini Rucker Coker, MD, MBA; Esa M. Davis, MD, MPH; Katrina E. Donahue, MD, MPH; Carlos Roberto Jaén, MD, PhD, MS; Martha Kubik, PhD, RN; Li Li, MD, PhD, MPH; Gbenga Ogedegbe, MD, MPH; Lori Pbert, PhD; John M. Ruiz, PhD; James Stevermer, MD, MSPH; Chien-Wen Tseng, MD, MPH, MSEE; John B. Wong, MD.
Affiliations of The US Preventive Services Task Force (USPSTF) members: University of California, Los Angeles (Mangione); Harvard Medical School, Boston, Massachusetts (Barry); University of North Carolina at Chapel Hill (Nicholson, Donahue); Albert Einstein College of Medicine, New York, New York (Cabana); Oregon Health & Science University, Portland (Caughey); Virginia Commonwealth University, Richmond (Chelmow); University of Washington, Seattle (Coker); University of Pittsburgh, Pittsburgh, Pennsylvania (Davis); University of Texas Health Science Center, San Antonio (Jaén); George Mason University, Fairfax, Virginia (Kubik); University of Virginia, Charlottesville (Li); New York University, New York, New York (Ogedegbe); University of Massachusetts Medical School, Worcester (Pbert); University of Arizona, Tucson (Ruiz); University of Missouri, Columbia (Stevermer); University of Hawaii, Honolulu (Tseng); Tufts University School of Medicine, Boston, Massachusetts (Wong).
Author Contributions: Dr Mangione had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The USPSTF members contributed equally to the recommendation statement.
Conflict of Interest Disclosures: Authors followed the policy regarding conflicts of interest described at https://www.uspreventiveservicestaskforce.org/Page/Name/conflict-of-interest-disclosures. All members of the USPSTF receive travel reimbursement and an honorarium for participating in USPSTF meetings.
Funding/Support: The USPSTF is an independent, voluntary body. The US Congress mandates that the Agency for Healthcare Research and Quality (AHRQ) support the operations of the USPSTF.
Role of the Funder/Sponsor: AHRQ staff assisted in the following: development and review of the research plan, commission of the systematic evidence review from an Evidence-based Practice Center, coordination of expert review and public comment of the draft evidence report and draft recommendation statement, and the writing and preparation of the final recommendation statement and its submission for publication. AHRQ staff had no role in the approval of the final recommendation statement or the decision to submit for publication.
Disclaimer: Recommendations made by the USPSTF are independent of the US government. They should not be construed as an official position of AHRQ or the US Department of Health and Human Services.
Additional Contributions: We thank Brandy L. Peaker, MD, MPH (AHRQ), who contributed to the writing of the manuscript, and Lisa Nicolella, MA (AHRQ), who assisted with coordination and editing.
Additional Information: The US Preventive Services Task Force (USPSTF) makes recommendations about the effectiveness of specific preventive care services for patients without obvious related signs or symptoms. It bases its recommendations on the evidence of both the benefits and harms of the service and an assessment of the balance. The USPSTF does not consider the costs of providing a service in this assessment. The USPSTF recognizes that clinical decisions involve more considerations than evidence alone. Clinicians should understand the evidence but individualize decision-making to the specific patient or situation. Similarly, the USPSTF notes that policy and coverage decisions involve considerations in addition to the evidence of clinical benefits and harms. Published by JAMA®—Journal of the American Medical Association under arrangement with the Agency for Healthcare Research and Quality (AHRQ). ©2022 AMA and United States Government, as represented by the Secretary of the Department of Health and Human Services (HHS), by assignment from the members of the United States Preventive Services Task Force (USPSTF). All rights reserved.
Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Division of Population Health. Basics about COPD. Reviewed 2021. Accessed October 5, 2021. https://www.cdc.gov/copd/basics-about.html
Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Division of Population Health. Chronic obstructive pulmonary disease (COPD) data and statistics. Reviewed 2021. Accessed October 5, 2021. https://www.cdc.gov/copd/data.html
KG , Nelson
AD , Laffey
MJ , Nguyen
Q , Sheets
LR , Schrum
AG . Chronic respiratory disease disparity between American Indian/Alaska Native and white populations, 2011-2018. BMC Public Health
. 2021;21(1):1466. doi:10.1186/s12889-021-11528-8PubMedGoogle ScholarCrossref
National Center for Health Statistics. Health, United States, 2019
. US Dept of Health and Human Services, Centers for Disease Control and Prevention; 2021. doi:10.15620/cdc:100685
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Published 2022. Accessed February 24, 2022. https://goldcopd.org/2022-gold-reports-2/
JS , Webber
EM , Thomas
RG . Screening for Chronic Obstructive Pulmonary Disease: A Targeted Evidence Update for the US Preventive Services Task Force. Evidence Synthesis No. 215. Agency for Healthcare Research and Quality; 2022. AHRQ publication 21-05287-EF-1.
AH , Davidson
KW , Mangione
et al; US Preventive Services Task Force. Interventions for tobacco smoking cessation in adults, including pregnant persons: US Preventive Services Task Force recommendation statement. JAMA
. 2021;325(3):265-279. doi:10.1001/jama.2020.25019PubMedGoogle ScholarCrossref
DK , Davidson
KW , Krist
et al; US Preventive Services Task Force. Primary care interventions for prevention and cessation of tobacco use in children and adolescents: US Preventive Services Task Force recommendation statement. JAMA
. 2020;323(16):1590-1598. doi:10.1001/jama.2020.4679PubMedGoogle ScholarCrossref
EM , Lin
JS , Thomas
RG . Screening for chronic obstructive pulmonary disease: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA
. Published May 10, 2022. doi:10.1001/jama.2022.4708Google Scholar
JM , Senger
CA , Webber
EM , Mularski
RA , Whitlock
EP . Screening for chronic obstructive pulmonary disease: evidence report and systematic review for the US Preventive Services Task Force. JAMA
. 2016;315(13):1378-1393. doi:10.1001/jama.2016.2654PubMedGoogle ScholarCrossref
A , Wilt
TJ , Weinberger
et al; American College of Physicians; American College of Chest Physicians; American Thoracic Society; European Respiratory Society. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med
. 2011;155(3):179-191. doi:10.7326/0003-4819-155-3-201108020-00008PubMedGoogle ScholarCrossref